Abbott Labs (ABT)

His favourite in this sector. They just delivered a monster quarter.

They report Wednesday. Are facing legal challenges that their baby formula kills, but last week the FDA and CDC cleared them. This could turn the tide.

They're turning around, given their immunotherapy pipeline, and their device and testing businesses are strong.

Pharma is challenged on growth, whereas devices have robust growth. Its device business has grown exceptionally well, between 10-12% organically. Overhang has been unfavourable comparisons from Covid testing. Reasonable valuation for quite a good company. Yield is 2%.

They lost a major court case last Friday and have to pay nearly $500 million in damages over its formula for premature babies. He feels the verdict is an outrage. Their formula saves lives and doctors recommend it.

They report on July 18. The company is doing very well, but they could lose a looming lawsuit. He wouldn't add more shares unless this breaks below $100.

Outlook is fabulous. Recent lawsuits turning out fine. Would buy at $100/share. 

Diversified businesses in medical devices, testing technology, pharma, nutrition. Selling off as a result of $60M judgement against competitor's infant formula, worries of contagion. Long-term, it will work out. 

Flat over the year. Wonderful product portfolio. Structural driver is heart/cardiac business. Reported yesterday, topline growth 2%. This number is misleading, as cardiac organic growth was 14%, and organic growth outside of diagnostics was 10%. Performing well, growing quite well, reasonable multiple. He'd buy today.

Yes, buy. Almost always they report and the reaction is negative at first, then it recovers. BTW, they had an excellent quarter.

They report Wednesday. Usually, shares climb after the report, then someone finds fault with a single line item, then shares fall. Buy on the dip the next day.

Likes healthcare in general, a larger weight for him. Chart's performing pretty decently relative to the S&P 500. Could give nice returns going forward. 

It's fallen so far and pays a good dividend. 

Medical devices, generics sold to EMs, nutrition. Lots of money during pandemic, money redeployed into new products. Attractive entry point. Yield is 2%, dividend increased every year.

It is a diversified global health care company with four operating divisions.  Sales dropped dramatically after benefiting during Covid but the basic business is doing well with all divisions growing organically. Weight loss patients are using their drugs to monitor glucose. It has had 51 years of dividend increases.             Buy 19  Hold 7  Sell 0